DANA-FARBER CANCER INSTITUTE
1. Target Overview & Investment Thesis
DANA-FARBER CANCER INSTITUTE is a 30-bed under-performing / distressed in SUFFOLK, MA with $1.88B in net patient revenue and a -35.1% operating margin. The hospital serves a payer mix of 35.1% Medicare, 1.6% Medicaid, and 63.3% commercial.
Thesis: Turnaround. Our ML models identify $138.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -35.1% to -27.7% (+736bps).
| Net Revenue HCRIS | $1.88B |
| Current EBITDA COMPUTED | $-660.4M |
| Operating Margin COMPUTED | -35.1% |
| Occupancy HCRIS | 87.8% |
| Revenue / Bed COMPUTED | $62.8M |
| Net-to-Gross HCRIS | 34.8% |
| Distress Probability ML | 1.7% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -35.1% places it below the state median. Among 16 size-comparable peers (15-60 beds), the median margin is -3.6%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (15-60), prioritizing same-state peers. 16 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| DANA-FARBER CANCER INSTITUTE (Target) | MA | 30 | $1.88B | -35.1% |
| MASSACHUSETTS EYE AND EAR INFI | MA | 41 | $263.9M | -36.1% |
| BETH ISRAEL DEACONESS HOSPITAL | MA | 58 | $131.9M | -1.6% |
| MARTHAS VINEYARD HOSPITAL | MA | 25 | $121.6M | 3.2% |
| FAIRVIEW HOSPITAL | MA | 24 | $94.5M | 19.8% |
| BAYSTATE WING HOSPITAL & MEDIC | MA | 40 | $91.8M | -16.8% |
| NASHOBA VALLEY HOSPITAL | MA | 57 | $70.7M | -2.0% |
| WALDEN BEHAVIORAL CARE | MA | 51 | $46.8M | 12.8% |
| REHAB HOSPITAL OF CAPE & ISLAN | MA | 60 | $44.3M | -17.0% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $138.7M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $39.6M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $37.7M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $37.3M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $22.9M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $1.2M | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-660.4M |
| + RCM Uplift | +$138.7M |
| Pro Forma EBITDA | $-521.8M |
| Current Margin | -35.1% |
| Pro Forma Margin | -27.7% |
| WC Released (1x) | $72.2M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-1.02B | $-2.97B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-1.02B | $-3.60B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-914.4M | $-3.47B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-914.4M | $-4.05B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-1.12B | $-3.33B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-1.12B | $-4.03B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 16 hospitals with 15-60 beds
- Same-state prioritization (n=17)
- Comp margins: P25=-19.2% / P50=-3.6% / P75=5.6%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.